Kala Pharmaceuticals, Inc. (KALA) financial statements (2021 and earlier)

Company profile

Business Address 490 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1541591851968598118
Cash and cash equivalents77461281968598118
Short-term investments7611457    
Receivables107451376
Inventory, net of allowances, customer advances and progress billings5865598
Inventory5865598
Prepaid expense2   2  
Other undisclosed current assets14241(1)1
Total current assets:171178197210105112133
Noncurrent Assets
Inventory, Noncurrent634443 
Operating lease, right-of-use asset2828292930  
Property, plant and equipment3333333
Restricted cash and investments12131313131313
Other undisclosed noncurrent assets01   3031
Total noncurrent assets:50474848494946
TOTAL ASSETS:222225246259154161179
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21181616231716
Accounts payable2221323
Accrued liabilities19161415211513
Debt   11  
Other undisclosed current liabilities211  12
Total current liabilities:22201717251818
Noncurrent Liabilities
Long-term debt and lease obligation991001001001007171
Long-term debt, excluding current maturities72727271717171
Finance lease, liability2728282829  
Other undisclosed noncurrent liabilities     2929
Total noncurrent liabilities:99100100100100100100
Total liabilities:122119117117125118118
Stockholders' equity
Stockholders' equity attributable to parent100106129142304361
Common stock0000000
Additional paid in capital500475470459325317311
Accumulated other comprehensive income (loss)0(0)(0)    
Accumulated deficit(400)(369)(341)(317)(295)(273)(250)
Total stockholders' equity:100106129142304361
TOTAL LIABILITIES AND EQUITY:222225246259154161179

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:2211112
Operating expenses(31)(28)(22)(21)(21)(23)(24)
Operating loss:(29)(26)(21)(20)(20)(22)(22)
Nonoperating income
(Investment Income, Nonoperating)
0000011
Interest and debt expense(2)(2)(2)(2)(2)(2)(2)
Net loss available to common stockholders, diluted:(31)(28)(23)(22)(22)(23)(24)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(31)(28)(23)(22)(22)(23)(24)
Other comprehensive income000    
Comprehensive loss, net of tax, attributable to parent:(31)(28)(23)(22)(22)(23)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: